斯德哥尔摩3在一个回顾性德国临床队列的外部验证
Derya Tilki1, Niclas Rejek2, Florian Nohe2
1Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey.
European urology focus
|August 7, 2024
概括
斯德哥尔摩3血液测试可以识别92%的临床上显著的前列腺癌病例,同时与PSA查相比,减少了52%的不必要的活检. 这可以改善早期检测和患者的治疗结果.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 生物标志物发现发现
背景情况:
- 前列腺癌的检测依赖于各种方法,包括PSA测试,它有局限性.
- 斯德哥尔摩3是一种新的血液测试,结合了蛋白质生物标志物,遗传指标和临床数据,用于前列腺癌风险评估.
- 对斯德哥尔摩3与现有方法的外部验证对于临床采用至关重要.
研究的目的:
- 在德国队列中对斯德哥尔摩3测试进行外部验证.
- 将斯德哥尔摩3与前列腺特异性抗原 (PSA) 和鹿特丹前列腺癌风险计算器 (RPCRC) 的性能进行比较,以检测临床显著的前列腺癌.
- 评估斯德哥尔摩提供的潜在减少不必要的活检3.
主要方法:
- 分析了405名在德国马丁尼诊所接受前列腺活检的男性的数据.
- 参与者是根据PSA升高或可疑的数字直肠检查来选择的.
- 评估了斯德哥尔摩3和RPCRC对临床显著前列腺癌检测的性能,将活检建议和结果与PSA水平进行比较.
主要成果:
- 斯德哥尔摩3表现出强烈的歧视 (AUC 0.80) 和良好的校准.
- 使用斯德哥尔摩3值 (≥15) 可以将不必要的活检减少52%,同时检测出92%的临床显著病例.
- 斯德哥尔摩3显示出积极的临床净益处,超过了基于RPCRC和PSA的标准.
结论:
- 斯德哥尔摩3在检测临床上显著的前列腺癌方面取得了显著的改进.
- 该测试可以大大减少不必要的前列腺活检的数量.
- 斯德哥尔摩3显示承诺作为早期前列腺癌检测和风险分层的宝贵工具.
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...